BAP Officer Details

Honorary Treasurer

Dr Michael Browning

Michael Browning

University of Oxford
Honorary Treasurer until 2024

The BAP fulfils a unique role in the UK. Its annual conference is the key national forum in which to present biological psychiatric research and to hear about recent advances. Its educational program, including clinical masterclasses and the non-clinical psychopharmacology course, provides evidence based information for both clinicians and non-clinical scientists. Lastly, the BAP’s pubic engagement activities help to promote a balanced understanding of the role of psychopharmacology. As a result, the BAP has become an essential component in supporting and encouraging the development of young researchers and in representing both psychopharmacology and biological psychiatry generally at the national level.

I am an academic psychiatrist with a research interest in the computational modelling of cognitive processes relevant to depression and anxiety. I utilise experimental medicine designs in studies which collect behavioural, subjective symptom and physiological data to test causal processes in depression and anxiety. I also run RCTs of treatment interventions and have worked in industry.

I have been a member of the BAP for the last 10 years or so and have been on the Council for the last 2 years. Over the last 10 years the BAP has supported me to attend oversees conferences (Robert Kerwin Bursary) and to disseminate my work (Senior Clinical Psychopharmacology Award) as well as providing a national platform to present my work. More importantly than this, most of the researchers and research active clinicians I know in the UK I have met at the BAP conference. For the BAP to continue to provide this facility to researchers it must remain economically viable, particularly with regards to the annual conference. As Treasurer I will work to ensure that a) the annual conference is developed as a meeting at which clinical and non-clinical researchers can share cutting edge results with the broader community, b) that the schemes which support the development of junior researchers (travel bursaries, small grants, prizes) are supported and that c) that the BAP remains relevant to its clinical and non-clinical members from academia, clinical practice and industry.

Declaration of Interests

  1. Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?
  2. No
  3. Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)
  4. I own shares in P1vital Products Ltd.
  5. Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
  6. I am employed (0.5 days/week) by P1vital Ltd
  7. Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
  8. I have acted as a consultant for J&J and CHDR
  9. Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
  10. No
  11. Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
  12. No
  13. Have you, in the past three years, had membership of the speakers' bureau for any company?
  14. No
  15. Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
  16. No
  17. Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
  18. No
  19. Have you, in the past three years, recruited patients for industry-sponsored studies?
  20. I have recruited patients to a study sponsored by J&J
  21. If there is anything else you feel it necessary to disclose, please provide details below:
  22. No

Form completed on 23rd July 2019